Angling to strengthen its position in Hunter syndrome by way of a method past the blood-brain barrier, Shire plc – already an investor in Armagen Technologies Inc. – paid $15 million up front and added an equity investment, sweetening the deal to develop the enzyme replacement therapy AGT-182 for somatic as well as central nervous system (CNS) effects of Hunter syndrome.